Xencor Inc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Xencor Inc Insights data

Headline Published Journalists
Showing 3 of 7 results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 17 Dec 2018 Lorem
Xencor reassesses XmAB5871 design for Phase III IgG4-RD study after SLE failure; YE18 target start, CMO says 26 Oct 2018 Krystnell Storr
Xencor’s XmAb5871 receives tepid response to Phase II lupus study; trial design a catch-22 for short and long-term efficacy, experts say 30 Aug 2018 Krystnell Storr
Xencor’s asthma drug XmAb7195 completes Phase Ia enrollment - CEO 08 Dec 2015 Alissa Fleck


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer